Crispr Therapeutics shares tumble after significant earnings miss
In a turbulent market environment, Leggett & Platt’s stock has touched a 52-week low, reaching a price level of $8.43 USD. This significant downturn reflects a broader trend for the diversified manufacturer, which has seen its shares plummet by 59.09% over the past year. Investors are closely monitoring the company’s performance, as this new low point has raised concerns about the underlying factors contributing to the stock’s prolonged decline and the potential for a rebound in the coming quarters. With analysts setting price targets between $11-12 and the stock currently trading below its Fair Value, InvestingPro offers 10+ additional exclusive insights about Leggett & Platt’s potential recovery prospects.
In other recent news, Leggett & Platt Incorporated reported its Q4 2024 earnings, revealing an earnings per share (EPS) of $0.21, which missed the forecasted $0.25. However, the company’s revenue of $1.1 billion exceeded expectations of $1.04 billion, highlighting strong operational execution. Despite the EPS miss, the robust revenue performance contributed to a 7.4% rise in after-hours stock trading. Analysts have noted the company’s strategic focus on green ventures and portfolio optimization as aligning with long-term growth plans. Leggett & Platt projects a potential 7% increase in adjusted funds from operations (AFFO) for 2025, alongside expected net core rent growth of 3.4% to 3.6%. The company is also targeting a reduction in its loan-to-value ratio to 45% in the mid-term. CEO Lars von Lachombe emphasized a conservative approach to financial management, reinforcing the company’s commitment to financial stability. Additionally, the integration of the BCP portfolio is expected to strengthen Leggett & Platt’s competitive stance, with further operational progress anticipated in the coming year.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.